Gsk (GSK) Change in Intangibles (2009 - 2026)

Gsk (GSK) recorded quarterly Change in Intangibles of -$299.3 million in Q1 2026, up 50.22% quarter-over-quarter from -$601.2 million in Q4 2025, and up 0.99% on a YoY basis from -$296.4 million in Q1 2025.

Gsk (GSK) Change in Intangibles (2009 - 2026) Analysis & Trends

Gsk's Change in Intangibles history runs 18 years deep, the most recent figure standing at -$299.3 million for Q1 2026.

  • In Q1 2026, Change in Intangibles rose 0.99% year-over-year to -$299.3 million; the TTM figure through Mar 2026 stood at -$2.2 billion (up 32.37% YoY), while the FY2025 annual figure was -$2.2 billion, down 6.67% from the prior year.
  • Change in Intangibles was -$299.3 million for Q1 2026 at Gsk, up from -$601.2 million in the prior quarter.
  • In the past five years, Change in Intangibles ranged from a high of -$176.7 million in Q2 2024 to a low of -$2.0 billion in Q4 2024.
  • Historically, Change in Intangibles has averaged -$626.3 million across 5 years, with a median of -$451.3 million in 2024.
  • The sharpest annual moves came in 2022 and 2025: Change in Intangibles jumped 82.56% in 2022, then tumbled 184.61% in 2025.
  • A 5-year view of Change in Intangibles shows it stood at -$1.3 billion in 2022, then advanced by 2.25% to -$1.3 billion in 2023, then tumbled by 58.93% to -$2.0 billion in 2024, then surged by 70.41% to -$601.2 million in 2025, then soared by 50.22% to -$299.3 million in 2026.
  • The last three Change in Intangibles figures came in at -$299.3 million (Q1 2026), -$601.2 million (Q4 2025), and -$766.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Intangibles (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn -299.30 Mn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn -
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn -
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn -
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn -
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn -
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn -
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn -
10 Novartis Ag 112.59 Bn 111.90 Bn - -461.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -299.30 Mn
Mar 31, 2026 -299.30 Mn
Dec 31, 2025 -601.24 Mn
Dec 31, 2025 -601.24 Mn
Sep 30, 2025 -766.44 Mn
Sep 30, 2025 -766.44 Mn
Jun 30, 2025 -502.94 Mn
Jun 30, 2025 -502.94 Mn
Mar 31, 2025 -302.28 Mn
Mar 31, 2025 -302.28 Mn
Dec 31, 2024 -2.03 Bn
Dec 31, 2024 -2.03 Bn
Sep 30, 2024 -697.72 Mn
Sep 30, 2024 -697.72 Mn
Jun 30, 2024 -176.71 Mn
Jun 30, 2024 -176.71 Mn
Mar 31, 2024 -399.58 Mn
Mar 31, 2024 -399.58 Mn
Dec 31, 2023 -1.28 Bn
Dec 31, 2023 -1.28 Bn